University of Washington Presenters at ISPOR, 2015, Philadelphia, Pennsylvania

Sunday, May 17, 2015
ISPOR Student Research Competition

6:30-8:30PM
Grand Ballroom, Salon C-D (Level 5)

UW TEAM: Blythe Adamson, Will Canestaro, Meng Li & Solomon Lubinga

Plenaries

Monday, May 18, 2015
8:40-8:50AM
Grand Ballroom, Salon A-F (Level 5)

Meeting Program Overview & Awards Session
Lou Garrison, PhD

Tuesday, May 19, 2015
8:30-10:30AM
Grand Ballroom, Salon A-F (Level 5)

SECOND PLENARY SESSION: COST-EFFECTIVENESS AND CLINICAL PRACTICE GUIDELINES: HAVE WE REACHED A TIPPING POINT?

Moderator: Lou Garrison, PhD
Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

WORKSHOPS
Monday, May 18
W1
5:00-6:00pm
Grand Ballroom, Salon A, B, F (Level 5)

PATIENT-CENTERED BENEFIT-RISK ANALYSIS: REGULATORY DEVELOPMENTS AND PROSPECTS

Discussion Leaders: F. Reed Johnson, PhD, Senior Research Scholar, Duke Clinical Research Institute, Duke University, Durham, NC, USA
John F.P. Bridges, PhD, Associate Professor, Department of Health Policy and Management and International Health, John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of
PODIUMS

Monday, May 18

HM: HEALTH CARE MANAGEMENT STUDIES
HM4
3:00 PM - 3:15 PM
Room: Grand Ballroom, Salon H (Level 5)

HOW MUCH EVIDENCE DO WE NEED BEFORE IMPLEMENTING PHARMACOGENOMIC TESTING IN THE CLINIC?
Guzauskas GF, Serbin M, Veenstra DL
University of Washington, Seattle, WA, USA

CS: RESEARCH ON COST STUDIES METHODS
CS3
3:45PM–4:45PM
Room: Grand Ballroom, Salon H (Level 5)

CURE MODELS: ACCOUNTING FOR CURED PATIENTS IN ECONOMIC EVALUATIONS
Othus M¹, Bansal A², Koepl L¹, Wagner S³, Ramsey S¹
¹Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA, ³Bristol-Myers Squibb, Washington Crossing, PA, USA

CN: CANCER OUTCOMES RESEARCH STUDIES
CN2
4:00 PM - 4:15 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)

A COMPARATIVE COST UTILITY ANALYSIS FOR FIRST LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
Carlson JJ¹, Slejko JF², Goertz H³, Veenstra DL¹
¹University of Washington, Seattle, WA, USA, ²University of Maryland, Baltimore, MD, USA, ³Genentech, South San Francisco, CA, USA

HT: HEALTH TECHNOLOGY ASSESSMENT STUDIES
HT2
4:00 PM - 4:15 PM
Room: Grand Ballroom, Salon G (Level 5)

APPLICATION OF COST-EFFECTIVENESS LOGIC TO US MANAGED CARE DRUG FORMULARIES: LONG TERM OUTCOMES OF A VALUE-BASED FORMULARY
Yeung K¹, Basu A², Hansen RN¹, Watkins J³, Sullivan SD²
HE: HEALTH CARE EXPENDITURE STUDIES
HE4
4:30 PM - 4:45 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)

OPTIMIZING CANCER CLINICAL TRIALS RESEARCH INVESTMENT DECISIONS IN THE UNITED STATES: A PROOF OF CONCEPT PORTFOLIO MANAGEMENT EVALUATION
Bennette CS\(^1\), Roth JA\(^2\), Basu A\(^1\), Carlson JJ\(^1\), Ramsey S\(^2\), Veenstra DL\(^1\)
\(^1\)University of Washington, Seattle, WA, USA, \(^2\)Fred Hutchinson Cancer Research Center, Seattle, WA, USA

POSTERS
MONDAY, MAY 18

PRM: RESEARCH ON METHODS
PRM63
8:30AM–2:15PM May 18, 2015
Room: Franklin Hall (Level 4)

FEASIBILITY AND ACCEPTABILITY OF MINIMAL MODELING VALUE OF INFORMATION ANALYSES FOR REAL-TIME PRIORITIZATION DECISIONS WITHIN A LARGE CANCER CLINICAL TRIALS COOPERATIVE GROUP
Bennette CS\(^1\), Veenstra DL\(^1\), Basu A\(^1\), Ramsey S\(^2\), Carlson JJ\(^1\)
\(^1\)University of Washington, Seattle, WA, USA, \(^2\)Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PDB: DIABETES/ENDOCRINE DISORDERS
PDB96
8:30AM–2:15PM May 18, 2015
Room: Franklin Hall (Level 4)

FINANCING A CURE FOR DIABETES IN A MULTI-PAYER ENVIRONMENT
Basu A\(^1\), Kamal-Bahl S\(^2\), Subedi P\(^3\)
\(^1\)University of Washington, Seattle, WA, USA, \(^2\)Pfizer, Philadelphia, PA, USA, \(^3\)Pfizer, New York, NY, USA

PDB: DIABETES/ENDOCRINE DISORDERS
PDB100
8:30AM–2:15PM May 18, 2015
Room: Franklin Hall (Level 4)

USE OF HEDIS A1C TARGETS IN CHARACTERIZING TREATMENT GOALS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING BASAL INSULIN
Oster G\(^1\), Moen D\(^2\), Yang T\(^3\), Dalal M\(^3\), Kazemi M\(^3\), Sung JC\(^3\), Traylor L\(^3\), Sullivan SD\(^4\)
\(^1\)Policy Analysis Inc., Brookline, MA, USA, \(^2\)MoenMDConsulting, St Paul, MN, USA, \(^3\)Sanofi US, Inc., Bridgewater, NJ, USA, \(^4\)University of Washington School of Pharmacy, Seattle, WA, USA

PMD: MEDICAL DEVICE/DIAGNOSTICS
PMD51
8:30AM–2:15PM May 18, 2015
Room: Franklin Hall (Level 4)

ESTIMATING THE COST-EFFECTIVENESS OF LEFT ATRIAL APPENDAGE CLOSURE COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

Shih V, Devine B
University of Washington, Seattle, WA, USA

PHP: HEALTH CARE USE & POLICY STUDIES
PHP37
3:45PM–7:45PM May 18, 2015
Room: Franklin Hall (Level 4)

A FRAMEWORK FOR STRENGTHENING PHARMACEUTICAL MANUFACTURING IN SUB-SAHARAN AFRICA

Mann M¹, Adamson BJ¹, Rennie T², Stergachis A¹
¹University of Washington, Seattle, WA, USA, ²University of Namibia, Windhoek, Namibia

PHP: HEALTH CARE USE & POLICY STUDIES
PHP59
3:45PM–7:45PM May 18, 2015
Room: Franklin Hall (Level 4)

WHEN IS HEALTH ECONOMICS AND OUTCOMES RESEARCH EVIDENCE IMPORTANT TO U.S. PAYERS?

Bajaj PS¹, Willke RJ², Basu A¹, Sullivan SD¹, Garrison LP¹
¹University of Washington, Seattle, WA, USA, ²Pfizer, Inc., New York, NY, USA

PHP: HEALTH CARE USE & POLICY STUDIES
PHP82
3:45PM–7:45PM May 18, 2015
Room: Franklin Hall (Level 4)

IMPACT OF CLINICAL AND HEALTH ECONOMIC PUBLICATIONS ON COMMERCIAL SUCCESS OF PHARMACEUTICAL PRODUCTS IN THE U.S

Slejko JF¹, Basu A², Sullivan SD³
¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Washington, Seattle, WA, USA, ³University of Washington School of Pharmacy, Seattle, WA, USA

PIH: INDIVIDUAL'S HEALTH
PIH19
3:45PM–7:45PM May 18, 2015
Room: Franklin Hall (Level 4)

IMPLICATIONS OF EMPLOYER COVERAGE OF CONTRACEPTION: COST-EFFECTIVENESS OF CONTRACEPTION UNDER AN EMPLOYER MANDATE

Canestaro WJ, Vodicka E, Downing D
University of Washington, Seattle, WA, USA

PIH: INDIVIDUAL'S HEALTH
PIH55
3:45PM–7:45PM May 18, 2015
Room: Franklin Hall (Level 4)
FACTORs IMPACTING PERSONALIZED MEDICINE TEST ADOPTION: EVALUATING PATIENT PREFERENCES AND WILLINGNESS TO PAY
Canestaro WJ1, Regier DA2, Veenstra DL1, Lavallee D1, Basu A1, Carlson JJ1
1University of Washington, Seattle, WA, USA, 2Canadian Centre for Applied Research in Cancer Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada

PMH: MENTAL HEALTH
PMH38
3:45PM–7:45PM May 18, 2015
Room: Franklin Hall (Level 4)

A COST-EFFECTIVENESS ANALYSIS OF ANTiPSYCHOTICS FOR TREATMENT OF SCHIZOPHRENIA IN UGANDA
Lubinga SJ1, Mutamba BB2, Nganizi A3, Babigumira JB1
1University of Washington, Seattle, WA, USA, 2Butabika National Referral Hospital for Mental, Neurological and Substance Abuse Disorders, Kampala, Uganda, 3Kadic Hospital, Kampala, Uganda

PMH: MENTAL HEALTH
PMH39
3:45PM–7:45PM May 18, 2015
Room: Franklin Hall (Level 4)

ESTIMATING THE COST-EFFECTIVENESS OF VORTIOXETINE VERSUS DESVENLAFAXINE AS FIRST LINE THERAPY FOR MILD TO MODERATE MAJOR DEPRESSIVE DISORDER IN REMITTED PATIENTS
Keyloun KR, Devine B
University of Washington, Seattle, WA, USA

PORPP/ISPOR Alumni & Friends Reception
5:00-8:00PM Monday, May 18
McGillin’s Olde Ale House
1310 Drury Street
Philadelphia, PA

Tuesday, May 19

Issue Panels III
2:15-3:15pm
Room: Grand Ballroom, Salon A, B, F (Level 5)
IP11
THE $2.6 BILLION QUESTION: WHY ARE DRUG DEVELOPMENT COSTS RISING AND CAN WE AFFORD IT? (Invited Issue Panel)
Moderator: Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA bio

POSTERS
MORTALITY AND READMISSION IN MECHANICALLY VENTILATED PATIENTS WITH PNEUMONIA
Hansen RN¹, Black DJ¹, Joish VN², Spilsbury-Cantalupo M², Sullivan SD¹
¹University of Washington School of Pharmacy, Seattle, WA, USA, ²Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA

ESTIMATING COST-EFFECTIVE DEVICE PRICES FOR PEDIATRIC COCHLEAR IMPLANTATION IN INDIA
Drennan WR, Banerjee S, Garrison L, University of Washington, Seattle, WA, USA

COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF INADEQUATELY RESPONDING RHEUMATOID ARTHRITIS PATIENTS
Hansen RN¹, Best JH², Sullivan SD³, Carlson JJ³
¹School of Pharmacy, University of Washington, Seattle, WA, USA, ²Genentech, Inc, South San Francisco, CA, USA, ³University of Washington, Seattle, WA, USA

DRUG THERAPY FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Canestaro WJ¹, Forrester S², Ho L¹, Devine B¹
¹University of Washington, Seattle, WA, USA, ²Group Health Cooperative, Seattle, WA, USA

ESTIMATING THE COST OF ILLNESS OF GIANT CELL ARTERITIS
Babigumira JB¹, Li M¹, Boudreau DM¹, Best JH², Garrison LP¹
¹University of Washington, Seattle, WA, USA, ²Genentech, Inc, South San Francisco, CA, USA
COMPARING TOTAL AND DISEASE SPECIFIC HEALTHCARE COSTS FOR GLAUCOMA PATIENTS BEFORE AND AFTER THEIR INDEX DIAGNOSIS: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS

Ye T\textsuperscript{1}, Patel V\textsuperscript{1}, Slejko JF\textsuperscript{2}, Devine B\textsuperscript{3}
\textsuperscript{1}Allergan, Inc, Irvine, CA, USA, \textsuperscript{2}University of Maryland School of Pharmacy, Baltimore, MD, USA, \textsuperscript{3}University of Washington, Seattle, WA, USA

PIN: INFECTION
PINS53
3:45PM–7:45PM May 19, 2015
Room: Franklin Hall (Level 4)

COST-EFFECTIVENESS ANALYSIS OF A PARTIALLY EFFECTIVE HIV VACCINE IN SAN FRANCISCO

Adamson BJ\textsuperscript{1}, Bounthavong M\textsuperscript{2}, Kublin JG\textsuperscript{3}, Garrison L\textsuperscript{4}
\textsuperscript{1}University of Washington, Seattle, WA, USA, \textsuperscript{2}Univer, SEATTLE, WA, USA, \textsuperscript{3}Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PCN: CANCER
PCN44
3:45PM–7:45PM May 19, 2015
Room: Franklin Hall (Level 4)

THE COSTS OF CANCER-RELATED ABSENTEEISM: A SYSTEMATIC REVIEW OF THE LITERATURE

Yu JS\textsuperscript{1}, Carlson JJ\textsuperscript{1} University of Washington, Seattle, WA, USA, \textsuperscript{2}Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

PCN: CANCER
PCN79
3:45PM–7:45PM May 19, 2015
Room: Franklin Hall (Level 4)

 IDEALISIB PLUS RITUXIMAB VERSUS PLACEBO PLUS RITUXIMAB FOR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: A COST-EFFECTIVENESS ANALYSIS

Yu JS\textsuperscript{1}, Seal B\textsuperscript{2}, Carlson JJ\textsuperscript{1}
\textsuperscript{1}University of Washington, Seattle, WA, USA, \textsuperscript{2}Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

PCN: CANCER
PCN90
3:45PM–7:45PM May 19, 2015
Room: Franklin Hall (Level 4)

COST-EFFECTIVENESS OF A BIOPSY-BASED 8-PROTEIN PROGNOSTIC ASSAY TO OPTIMIZE TREATMENT DECISIONS IN GLEASON 3+3 AND 3+4 PROSTATE CANCER

Roth JA\textsuperscript{1}, Ramsey S\textsuperscript{2}, Carlson JJ\textsuperscript{2}
\textsuperscript{1}Fred Hutchinson Cancer Research Center, Seattle, WA, USA, \textsuperscript{2}University of Washington, Seattle, WA, USA

PCN: CANCER
PCN117
3:45PM–7:45PM May 19, 2015
Room: Franklin Hall (Level 4)

INCLUSION OF PATIENT-REPORTED OUTCOME MEASURES IN REGISTERED CLINICAL TRIALS: EVIDENCE FROM CLINICALTRIALS.GOV (2007-2013)
AN EVALUATION OF CLINICAL REMISSION AND SAFETY AMONG BIOLOGICS FOR MODERATE-TO-SEVERE CROHNS DISEASE: A BAYESIAN NETWORK META-ANALYSIS

Bounthavong M¹, Bae YH², Vanness DJ³, Kazerooni R⁴, Devine B⁵
¹University of Washington, Seattle, WA, USA, ²WESTERN UNIVERSITY OF HEALTH SCIENCES, POMONA, CA, USA, ³University of Wisconsin-Madison, Madison, WI, USA, ⁴Veterans Affairs San Diego Healthcare System, San Diego, CA, USA, ⁵University of Washington, Seattle, WA, USA

A COST-UTILITY ANALYSIS OF BIOLOGICS FOR MODERATE-TO-SEVERE CROHN'S DISEASE: EVIDENCE SYNTHESIS USING A BAYESIAN NETWORK META-ANALYSIS

Bounthavong M¹, Bae YH², Devine B³, Veenstra DL³
¹University of Washington, Seattle, WA, USA, ²WESTERN UNIVERSITY OF HEALTH SCIENCES, POMONA, CA, USA, ³University of Washington, Seattle, WA, USA

Wednesday, May 20

Workshops IV

W22
1:45-2:45pm
Grand Ballroom, Salon H (Level 5)

HOW TO DESIGN AN ANALYTIC STRATEGY FOR EVIDENCE GENERATION FOR DECISION MAKERS

Discussion Leaders: Sean D. Sullivan, PhD, Professor & Dean, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

Omar Dabbous, MD, MPH, Head of Quantitative Sciences, Payer Evidence Group, GlaxoSmithKline, King of Prussia, PA, USA

Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Workshops V

W29
3:00-4:00pm
Grand Ballroom, Salon G (Level 5)

STRATEGIES FOR ASSESSING THE PATIENT-LEVEL ECONOMIC IMPACT OF CANCER DIAGNOSIS

Discussion Leaders: Veena Shankaran, MD, MS, Assistant Professor, Division of Medical Oncology, University of Washington, Seattle, WA, USA
Amy Davidoff, PhD, MS, Senior Research Scientist, Cancer Prevention and Control, Yale School of Public Health, New Haven, CT, USA
Donatus Ekwueme, PhD, Senior Health Economist, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Chamblee, GA, USA

POSTERS

PHS: HEALTH SERVICES
PHS2
8:30AM–2:45PM May 20, 2015
Room: Franklin Hall (Level 4)

SENTINEL SITE ACTIVE SURVEILLANCE OF THE SAFETY OF FIRST-LINE ANTIRETROVIRAL MEDICINES IN NAMIBIA
Mann M¹, Mengistu A², Gaeseb J³, Sagwa E⁴, Mazibuko G⁴, Garrison LP¹, Stergachis A¹
¹University of Washington, Seattle, WA, USA, ²Therapeutics Information and Pharmacovigilance Centre Namibia, Windhoek, Namibia, ³Ministry of Health and Social Services Namibia, Windhoek, Namibia, ⁴Management Sciences for Health, Windhoek, Namibia

PSY: SYSTEMIC DISORDERS/CONDITIONS
PSY56
8:30AM–2:45PM May 20, 2015
Room: Franklin Hall (Level 4)

SYSTEMATIC REVIEW OF THE PATTERNS OF USE, CHARACTERISTICS, AND QUALITY OF PATIENT REPORTED OUTCOME MEASURES IN CELIAC DISEASE
Canestaro WJ, Edwards TC, Patrick DL
University of Washington, Seattle, WA, USA